Hemadsorption in patients requiring V-A ECMO support: Comparison of Cytosorb versus Jafron HA330.

Timur LesbekovZhuldyz NurmykhametovaRymbay KaliyevAidyn KuanyshbekLinar FaizovBolat BekishevNilufar JabayevaRobertas SamalaviciusYuriy Pya

Published in: Artificial organs (2022)

At the time of writing, hemadsorption in patients requiring V-A ECMO support represents a good therapeutic effect. This effect is permanent for the whole period of extracorporeal cytokine hemadsorption application for both CytoSorb and Jafron HA330 devices.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
extracorporeal membrane oxygenation
peritoneal dialysis
acute respiratory distress syndrome
intensive care unit
patient reported outcomes